A Phase 1 interventional study of ASC36 Injection A, for subcutaneous use and ASC36 Placebo Injection A, for subcutaneous use in Chronic Weight Management, sponsored by Ascletis Pharma (China) Co., Limited. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Ascletis Pharma (China) Co., Limited (part of Ascletis Pharma Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Two Formulations of ASC36 injection
11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.
This study's planned enrollment of 144 is above the median of 67 across 9,036 interventional studies indexed under Obesity.
Browse Obesity studies →Ascletis Pharma (China) Co., Limited is the lead sponsor of 12 studies on the registry; 5 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participant is eligible to participate if she is not pregnant, breastfeeding, or planning to breastfeed, and one of the following conditions applies:
Exclusion Criteria:
Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or abnormal liver enzymes as defined as follows at screening.
Have an (ECG) abnormality at screening as defined as follows:
Have poorly controlled high blood pressure per Investigator's judgment during screening:
i. systolic blood pressure (SBP) ≥160 mmHg
ii. diastolic blood pressure (DBP) ≥100 mmHg
Have the following lab findings at screening:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SAD Dose 1 for Formulation A
Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use
SAD Dose 2 for Formulation A
Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use
SAD Dose 3 for Formulation A
Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use
SAD Dose 4 for Formulation A
Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use
MAD Dose 1 for Formulation A
Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use
MAD Dose 2 for Formulation A
Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use
MAD Dose 3 for Formulation A
Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use
MAD Dose 4 for Formulation A
Drug: ASC36 Injection A, for subcutaneous use · Drug: ASC36 Placebo Injection A, for subcutaneous use
SAD Dose 1 for Formulation B
Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use
SAD Dose 2 for Formulation B
Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use
SAD Dose 3 for Formulation B
Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use
SAD Dose 4 for Formulation B
Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use
MAD Dose 1 for Formulation B
Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use
MAD Dose 2 for Formulation B
Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use
MAD Dose 3 for Formulation B
Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use
MAD Dose 4 for Formulation B
Drug: ASC36 Injection B, for subcutaneous use · Drug: ASC36 Placebo Injection B, for subcutaneous use
ASC36 Injection A is an investigational formulation of ASC36 administered by subcutaneous injection.
ASC36 Placebo Injection A is an placebo injection matching ASC36 Injection A.
ASC36 Injection B is an investigational formulation of ASC36 administered by subcutaneous injection.
ASC36 Placebo Injection B is an placebo injection matching ASC36 Injection B.
Adverse Events
A summary of AEs, SAEs, and other non-serious adverse events following single SC doses of ASC36 injection
Time frame: From baseline to the end of treatment (up to 16 weeks or Day 113)
Adverse Events
A summary of AEs, SAEs, and other non-serious adverse events following multiple SC doses of ASC36 injection
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Cmax of ASC36 Injection
Evaluate the peak plasma concentration of ASC36 Injection
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Tmax of ASC36 Injection
Evaluate the time to reach peak plasma concentration of ASC36 Injection
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
AUC of ASC36 Injection
Evaluate the area under the plasma concentration-time curve of ASC36 Injection
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Half-life of ASC36 Injection
Evaluate the time required for the plasma concentration of ASC36 to decrease by 50%
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Percent Change From Baseline in Body Weight
Percent Change From Baseline in Body Weight
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Percent Change From Baseline in Waist Circumference
Percent Change From Baseline in Waist Circumference
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Percent Change From Baseline in BMI
Percent Change From Baseline in BMI
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Immunogenicity of ASC36 Injections
Incidence and prevalence of treatment-emergent antidrug antibodies against ASC36 after SC doses of ASC36 injection
Time frame: From baseline to the end of treatment (up to 20 weeks or Day 141)
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2026 (actual). Primary completion is estimated for Jun 2027, 9 months after the start.
Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 9 months is close to that.
Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ascletis Pharma (China) Co., Limited →